» Articles » PMID: 24375982

Association Between Inflammatory Biomarkers and Bone Mineral Density in a Community-based Cohort of Men and Women

Overview
Specialty Rheumatology
Date 2013 Dec 31
PMID 24375982
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Based upon evidence in animal and in vitro studies, we tested the hypothesis that higher serum concentrations of the cytokines interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) and the inflammatory marker C-reactive protein (CRP) would be inversely associated with bone mineral density (BMD) in a community-based cohort of men and women, with the strongest associations among postmenopausal women not receiving menopause hormonal therapy (MHT).

Methods: We ascertained fasting serum concentrations of IL-6, TNFα, and CRP and measured BMD at the femoral neck, trochanter, total femur, and spine (L2-L4) using dual x-ray absorptiometry in 2,915 members of the Framingham Offspring Study (1996-2001). We used multivariable linear regression to estimate the difference (β) in BMD at each bone site associated with a 1-unit increase in log-transformed serum concentrations of IL-6, TNFα, and CRP separately for men (n = 1,293), premenopausal women (n = 231), postmenopausal women receiving MHT (n = 498), and postmenopausal women not receiving MHT (n = 893).

Results: Inflammatory biomarkers were not associated with BMD in men. Among premenopausal women, there were statistically significant, modest inverse associations between IL-6 and trochanter BMD (β = -0.030, P < 0.01) and between CRP and femoral neck (β = -0.015, P = 0.05) and trochanter BMD (β = -0.014, P = 0.04). TNFα was positively associated with spine BMD (β = 0.043, P = 0.01). In postmenopausal women receiving MHT, CRP was positively associated with femoral neck BMD (β = 0.011, P = 0.04). There were no associations among postmenopausal women not receiving MHT.

Conclusion: The lack of consistency in our results suggests that elevated circulating concentrations of inflammatory biomarkers may not be a risk factor for low BMD.

Citing Articles

Bone Mineral Density, Bone Biomarkers, and Joints in Acute, Post, and Long COVID-19: A Systematic Review.

Alghamdi F, Mokbel K, Meertens R, Obotiba A, Alharbi M, Knapp K Viruses. 2024; 16(11).

PMID: 39599809 PMC: 11599111. DOI: 10.3390/v16111694.


Femoral bone mineral density as a tool of personalized medicine for rheumatoid arthritis: Interleukin-6 inhibitors for patients with low density whereas tumor necrosis factor inhibitor for patients with preserved density?.

Takaoka H, Miyamura T, Shimada K SAGE Open Med. 2024; 12:20503121241277498.

PMID: 39315386 PMC: 11418348. DOI: 10.1177/20503121241277498.


An exploration of the causal relationship between 731 immunophenotypes and osteoporosis: a bidirectional Mendelian randomized study.

Zhou D, Zi C, Gan G, Tang S, Chen Q Front Endocrinol (Lausanne). 2024; 15:1341002.

PMID: 39086903 PMC: 11288873. DOI: 10.3389/fendo.2024.1341002.


Navigating the gut-bone axis: The pivotal role of Coprococcus3 in osteoporosis prevention through Mendelian randomization.

Ma J, Wang X, Zhou Y, Zhou W, Zhang J, Sun C Medicine (Baltimore). 2024; 103(29):e38861.

PMID: 39029026 PMC: 11398822. DOI: 10.1097/MD.0000000000038861.


Association of neutrophil to lymphocyte ratio with bone mineral density in post-menopausal women: a systematic review and meta-analysis.

Salimi M, Khanzadeh M, Nabipoorashrafi S, Seyedi S, Yaghoobpoor S, Brismee J BMC Womens Health. 2024; 24(1):169.

PMID: 38461235 PMC: 10924380. DOI: 10.1186/s12905-024-03006-1.


References
1.
Khosla S, Peterson J, Egan K, Jones J, Riggs B . Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab. 1994; 79(3):707-11. DOI: 10.1210/jcem.79.3.8077350. View

2.
Ganesan K, Teklehaimanot S, Tran T, Asuncion M, Norris K . Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc. 2005; 97(3):329-33. PMC: 2568626. View

3.
Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y . Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993; 90(24):11924-8. PMC: 48097. DOI: 10.1073/pnas.90.24.11924. View

4.
Madhok R, Crilly A, Watson J, Capell H . Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993; 52(3):232-4. PMC: 1005024. DOI: 10.1136/ard.52.3.232. View

5.
Johnell O, Kanis J . Epidemiology of osteoporotic fractures. Osteoporos Int. 2004; 16 Suppl 2:S3-7. DOI: 10.1007/s00198-004-1702-6. View